amitriptyline + lithium carbonate

Amitriptyline + lithium carbonate is a combination of two pharmaceutical agents used primarily in the management of mood disorders, particularly treatment-resistant depression and bipolar disorder. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, increasing their synaptic concentrations in the central nervous system. Lithium carbonate is a mood stabilizer whose precise mechanism remains unclear but is thought to involve inhibition of enzymes such as glycogen synthase kinase 3 (GSK-3) and modulation of inositol monophosphatase activity, affecting neurotransmitter signaling pathways. The combination has been studied for its potential to rapidly alleviate depressive symptoms in patients unresponsive to tricyclic antidepressants alone, likely through synergistic enhancement of serotonergic neurotransmission[1][3]. However, clinical studies have not consistently shown superior efficacy for the combination over monotherapy with either agent[1][3].